

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at 9:05 AM
Continue Reading
SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and
Continue Reading
Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and
Continue Reading
SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision
Continue Reading
EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.
Continue Reading
SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision
Continue Reading
SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision
Continue Reading
SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision
Continue Reading
More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) — Myriad
Continue Reading